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ess: cky07460@moon.oSummary Many patients with severe refractory asthma, which is insufficiently
controlled by additional high-dose of inhaled corticosteroids, require oral
corticosteroids and/or immunosuppressant. Clinicians should seek for suitable
medications, for its’ chronic use may induce high risk of side effects.
The purpose of this study was to evaluate the efficacy and safety of nebulized sodium
cromoglycate (3–4 times/day) in adult severe asthmatic patients with poorly controlled
asthmatic symptoms, despite treatments with high-dose inhaled corticosteroids.
Adult patients with severe asthma (n ¼ 251) were enrolled in a randomized clinical
trial at 30 medical centers in Japan. Isotonic saline was used as placebo. The study was
conducted for 10 weeks; with initial 2 weeks of observation followed by 8 weeks of
treatments. Efficacy was primarily evaluated based on improvements in morning peak
expiratory flow after treatment.
All patients who applied inhalation of nebulized sodium cromoglycate (SCG group) or
saline (Controls) were treated with high-dose of inhaled corticosteroids (median of
beclomethasone dipropionate equivalent dose: 1600mg/day s) and second-line control
therapy including oral corticosteroids. There was no significant difference in morning
peak expiratory flow between SCG group and controls. However, when patients were
stratified into atopic and non-atopic groups, morning peak expiratory flow had
significantly improved in the atopic SCG group compared to atopic Controls.
Additional inhalation of nebulized sodium cromoglycate with inhaled corticosteroids
is effective even in patients with severe atopic asthma. This finding shows that
nebulized sodium cromoglycate is expected to be new second-line therapeutic option in
severe asthma.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
625 6381; fax: +81 3 5619 8722.
dn.ne.jp (Y. Sano).
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Currently, asthma treatment guidelines1,2 had
recommended inhaled corticosteroids as first-line
control therapy on asthma, and emphasized the
combination of other medications (e.g., long-
acting inhaled b2 agonists, leukotriene receptor
antagonists (LTRAs), and slow-acting theophylline
drugs) as second-line control therapy, with higher
dose of inhaled corticosteroids in patients with
more severe asthma. However, many patients with
severe refractory asthma3 are not fully controlled
despite treatments with high-dose of inhaled
corticosteroids and other medications. Moreover,
increasing dose of inhaled corticosteroids or initia-
tion of oral corticosteroids and/or immunosuppres-
sant is restricted in patients with anti-inflammatory
treatments. Since treatments with oral corticos-
teroids and/or immunosuppressant present risks of
side effects, development of therapeutic options
not causing dependence on oral corticosteroids
and/or immunosuppressant should essentially be
considered.
Sodium cromoglycate (SCG) is an anti-inflamma-
tory agent that acts via different mechanisms
against corticosteroids. Several studies4–7 have
evaluated the effects of SCG in the long-term
management against mild-to-moderate asthma.
Nebulized SCG improves airway obstruction caused
by excessive production of sputum, relieves per-
ipheral airway inflammation, and synergism is seen
with inhaled corticosteroids or b2 agonists. This
pharmacotherapy is thus considered to be effective
against severe asthma.8 However, few studies have
reported the characteristics of patient who shows
synergism between nebulized SCG and inhaled
corticosteroids.
In this study, the efficacy and safety of nebulized
SCG was evaluated in patients with severe asthma,
which was inadequately controlled even with high-
dose of inhaled corticosteroids plus other medica-
tions, by comparing isotonic saline as a control.
Stratified analysis was also performed to clarify the
effects of nebulized SCG.Methods
Study design
In this study, randomized study was performed by
using isotonic saline as a control therapy, at 30
medical centers in Japan. The duration of this study
was 10 weeks; 2 weeks of observation to evaluate
patients before therapy, followed by 8 weeks oftreatment to evaluate the efficacy of nebulized
SCG. Nebulized SCG (20mg of SCG per ampule
(2mL)) was used as a trial drug (SCG group), and
nebulized saline (18mg of sodium chloride per
ampule (2mL)) was used as a control drug (Con-
trols). Both drugs were inhaled 3–4 times/day using
electronic nebulizer (Pari Boy 038s LL Nebulizer;
Pari innovative manufacturers, 13800 Hull Street
Rd, Midlothian, VA). The biostatistics advisor had
randomly assigned treatments on a key code table
blindly, and disclosed them after the database was
locked.
Study objectives were explained to the patients
thoroughly and written informed consent was
obtained prior to the study. All study protocols
were approved by the institutional review board
and the director of each participating medical
institution.Patients
Patients at the age of 20 and older, diagnosed as
severe persistent asthma, were enrolled in this
study; Step 4 (Table 1) according to the Classifica-
tion for Asthma Severity in the Asthma Prevention
and Management Guidelines 20001 in Japan. All
patients had been using one of the following
inhaled corticosteroid regimens prior to the study:
4800 mg/day of inhaled beclomethasone dipropio-
nate (BDP-CFC), 4400 mg/day of inhaled flutica-
sone propionate (FP-DPI), or 4400 mg/day of
inhaled budesonide (BUD-DPI). Patients who were
using either BDP-CFC 800 mg/day, FP-DPI 400 mg/
day, or BUD-DPI 400 mg/day in combination with
oral corticosteroids were also eligible when total
dose of steroid exceeded the BDP equivalent dose
mentioned above. Additional eligibility criteria
were as follows: mean morning peak expiratory
flow (PEF) during the observation period o80% of
normal predicted value,1 or diurnal variation in PEF
during the observation period 420% were evalu-
ated at least 2 days/each week; asthmatic symp-
toms (wheezing, dyspnea, or slight asthmatic
attack) were reported at least 2 times/week.
Moreover, patients who present specific IgE anti-
bodies against environmental allergens (high in
serum total IgE levels, allergen-specific IgE posi-
tive, and/or allergy skin test positive) were
classified as atopic (allergic) asthma. Patients
without specific IgE antibodies were classified as
non-atopic (non-allergic) asthma.
Patients were excluded from the study if: (1)
allergen immunotherapy or other non-specific
immunotherapy was initiated p6 months
before the observation period, (2) initiation
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Table 1 The features of severe persistent asthma
according to the Classification for Asthma Severity
in the Asthma Prevention and Management Guide-
lines 2000 in Japan (1998 Revised version 1).
Characteristics of symptoms
Frequent exacerbation (despite treatment)
Persistent symptoms
Limitation of daily activities
Frequent nocturnal symptoms
(Daily use of oral steroids)
PEF
o60% of personal best or predicted value
FEV1.0
430% variation
Treatment (long-term management)
 Inhaled corticosteroids
J High-dose
J Beclomethasone dipropionate 800–1600mg/
day
J Fluticasone propionate 400–800 mg/day
J Daily
 Short-term of moderate to high-dose oral
steroids, followed by maintenance therapy at
lowest dose possible; every other day or once
daily.
J Daily administration of slow-acting
theophylline
J Daily administration of topical, inhaled, or
oral b2 agonist
J (Anti-allergic drugs)
– Consider daily use of leukotriene
antagonist or thromboxane A2 inhibitor/
antagonist
 During athmatic attacks
J Additional use of inhaled b2 agonist as
needed (maximum of 3–4 times/day)
Y. Sano et al.422of anti-allergic drugs or LTRAs, switching to another
drugs, or use of depo-steroid p3 months before
the observation period was enforced, (3) initiation
of allergen immunotherapy, other non-specific
immunotherapy, anti-allergic drugs, or LTRAs,
switching to another drugs, use of depo-steroid
during the observation period was enforced,
or (4) administration of oral steroid 410mg/day
(predonisolone), changes in dosage of oral
steroids, administration of steroid infusion or
injection, initiation of long-acting b2 agonist
(inhaled, oral, or topical), oral slow-acting
theophylline, inhaled b2 agonist by nebulizer, or
administration of X3 infusions or injections of
bronchodilator (e.g., aminophylline) per week
were applied.Evaluation
Outpatients were scheduled to visit medical
centers at the start of the observation period
for 2 weeks, and at 0, 2, 4, 6 and 8 weeks of
treatment period. Patients were instructed to
keep records of asthmatic symptoms, PEF values,
and treatments each day during the week. PEF
was measured twice daily, morning (within 30min
of waking) and evening, with peak flow meter
(Mini-Wrights; Clement Clark International, Har-
low, UK). PEF were measured 3 times each in
standing position, before the administration of
asthmatic medications, and the highest value
was recorded. Mean PEFmorning and PEFevening
were calculated each week. Asthmatic symp-
toms were scored based on the standard evalua-
tion criteria.9 They are as follows: asthmatic attack
and wheezing on a scale of 0–9 (0 point: no
symptoms, 1 point: dyspnea or wheezing, 3 points:
slight attack, 6 points: moderate attack, 9 points:
severe attack), cough on a scale of 0.5–1 (0.5
point: infrequent cough, 1 point: frequent cough).
Treatment status was scored in each concomi-
tant drugs based on the standard evaluation
criteria.9 Pulmonary function was evaluated by
spirometer at the start of the treatment, 4 weeks
after the initiation of the treatment, and at
the end of the treatment. This included forced
vital capacity (FVC), forced expiratory volume
in 1 s (FEV1.0), and FEV1.0/FVC ratio (%FEV1.0).
At the start and the end of the treatment,
Airways Questionnaire 20 (AQ20)10 regarding qual-
ity of life (QOL) was answered by the patients. The
AQ20 was comprised of 20 questions. The questions
inquired about the effect of chest troubles in
everyday life. ‘Yes’ responses were scored ‘‘1’’,
‘No’ and ‘N/A(Not Applicable)’ responses were
scored ‘‘0’’.
As asthmatic patients often present prominent
morning dip in PEF,11 PEFmorning was used as primary
evaluation tool in this study.
Type, severity, time of onset, specific treatment,
follow-up, and time of resolution were documented
for all adverse events occurred during the
study. Patients were monitored closely as possible
until the resolution or improvement of symptoms
was observed. These adverse events, which a
relationship with the treatment of this study could
not be denied, were considered as adverse drug
reactions.
Any patients who required emergency treatment
such as additional oral, injectable, or infused
steroids to treat exacerbation of asthmatic symp-
toms were judged by the investigator, and imme-
diately withdrawn from the study.
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The percentage change from baseline at each time
point in PEFmorning and PEFevening was analyzed by
using 2-sample Wilcoxon test between treatment
groups. The change from baseline at each time
point in PEFmorning and PEFevening was also analyzed
by the same method. In addition, incidence of
responder patients in a contingency table was
analyzed by Fisher’s exact probability test between
treatment groups. Patients were defined as ‘‘re-
sponders’’ for those who has improved more than or
equal to 20 L/min from baseline at the end of
treatment in PEFmorning, and as ‘‘non-responders’’
for those less than 20 L/min, to explore the clinical
significance. The above-mentioned specified that
the primary endpoint was the percentage change
from baseline at the end of the treatment in
PEFmorning. For the change from baseline at each
time point in pulmonary functions (FVC, FEV1.0,
%FEV1.0), asthmatic symptom score and medication
score was analyzed in the same way as in PEF. The
change from baseline at the end point in QOL was
analyzed by 2-sample t-test between treatment
groups. The incidence of treatment discontinuation
due to symptom aggravation was analyzed by using
Fisher’s exact probability test between treatment
groups. The incidence of adverse events, treatment
discontinuation due to adverse events, and adverse
drug reactions were analyzed by the same method.
Demographics and baseline characteristics were
analyzed by using Fisher’s exact probability test for
categorical variables and 2-sample Wilcoxon test
for continuous variables. All efficacy were analyzed
in the Full Analysis Set (FAS), and safety analyses
were done on all patients with treatment and
safety data, utilizing SAS Release 8.02. All statis-
tical tests were conducted at a 2-sided 0.05
significance level.Results
Background of the patients
Among 251 patients (SCG group, n ¼ 128; Controls,
n ¼ 123) enrolled in the study, 23 patients (SCG
group, n ¼ 14; Controls, n ¼ 9) were excluded from
efficacy analysis; this included 21 patients (SCG
group, n ¼ 13; Controls, n ¼ 8) with protocol
violations and 2 patients (SCG group, n ¼ 1;
Controls, n ¼ 1) with no treatment. Thus, 228
patients (SCG group, n ¼ 114; Controls, n ¼ 114)
were analyzed for efficacy. Five patients (SCG
group, n ¼ 4; Controls, n ¼ 1) were excluded fromsafety analysis; this included 3 patients (SCG group,
n ¼ 3) with no safety data and 2 patients (SCG
group, n ¼ 1; Controls, n ¼ 1) with no treatment.
Thus, 246 patients (SCG group, n ¼ 124; Controls,
n ¼ 122) were analyzed for safety.
In analysis of clinical characteristics, asthmatic
symptom score was significantly higher in Controls
than in the SCG group. However, no differences were
identified between the 2 groups regarding sex, age,
height, disease type, duration of asthma, atopic
complications, respiratory complications and/or
chronic sinusitis, treatment score, PEFmorning, inci-
dence of normal predicted PEFmorning, pulmonary
function, or QOL score (Table 2).
Median dosage of inhaled corticosteroids used
during the observation period was BDP-CFC equiva-
lent dose of 1600 mg/day in both SCG group and
Controls. In addition to inhaled corticosteroids,
other asthmatic medications were administered in
all patients: LTRAs, n ¼ 118 (51.8%; SCG group,
n ¼ 56; Controls, n ¼ 62); oral slow-acting theo-
phylline, n ¼ 202 (91.2%; SCG group, n ¼ 105;
Controls, n ¼ 97); long-acting b2 agonists, n ¼ 161
(70.6%; SCG group, n ¼ 85; Controls, n ¼ 76); and
short-acting inhaled b2 agonists, n ¼ 168 (73.7%;
SCG group, n ¼ 82; Control, n ¼ 86). In addition,
oral corticosteroids, with a median dosage of 5mg/
day (prednisolone equivalent dose), were used in
97 patients (42.5%; SCG group, n ¼ 49; Controls,
n ¼ 48) in both SCG group and Controls (Table 3).Efficacy
Median percentage change (change) in PEFmorning,
between observation period and end of treatment,
was 3.50%( 8.25 L/min) in the SCG group and
1.67%(6.00 L/min) in Controls, with no significant
difference was identified between groups
(P ¼ 0:655) (Table 4a, Fig. 1). Median percentage
change (change) in PEFevening, between observation
period and end of treatment was 1.16% (3.25 L/
min) in the SCG group and 1.56% (5.50 L/min) in
Controls, with no significant difference was identi-
fied between groups (P ¼ 0:609).
Stratified analysis of changes in PEFmorning among
atopic subgroup was significantly higher in the SCG
group compared to Controls at 2 weeks, 4 weeks
and end of treatment (Fig. 2, Table 4b). Stratified
analysis of changes in PEFmorning among non-atopic
subgroup showed no significant difference between
the SCG group and Controls (Fig. 3, Table 4b).
The incidence of responders for PEFmorning re-
vealed response rate of 34.8% (n ¼ 39 vs. n ¼ 112)
in the SCG group and 24.8% (n ¼ 28 vs. n ¼ 113) in
Controls, with no significant difference (P ¼ 0:110).
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Table 2 Demographics and baseline characteristics.
SCG group
(n ¼ 114)
Controls
(n ¼ 114)
P-value
Sex (male/female) 62/52 55/59 0.427
Age (mean7SD) (years) 58.9713.28 57.3713.18 0.312
Height (mean7SD) (cm) 159.2278.151 159.5677.760 0.955
Type (atopic/non-atopic) 69/45 67/47 0.893
Duration of asthma
Median 14.25 16.00 0.775
Q1–Q3 8.00–24.17 8.25–25.00
Atopic complications (no/yes) 63/51 69/45 0.503
Respiratory complications and/or chronic
sinusitis (no/yes)
98/16 99/15 1
Asthmatic symptom score
Median 20.12 23.88 0.022
Q1–Q3 7.25–33.50 15.00–35.25
Treatment score (points)
Median 174.73 172.95 0.788
Q1–Q3 147.10–205.90 141.85–219.10
PEFmorning (L/min)
Median 282.25 260.00 0.172
Q1–Q3 222.00–337.00 200.50–331.50
Incidence of normal predicted PEFmorning (%)
Median 60.17 54.48 0.203
Q1–Q3 46.44–70.59 41.45–69.44
FVC (mL)y
Median 2430 2430 0.886
Q1–Q3 1900–3250 1970–3020
FEV1.0 (mL)
y
Median 1500 1540 0.788
Q1–Q3 1130–2040 1140–2060
%FEV1.0 (%)
y,z
Median 63.2 66.37 0.679
Q1–Q3 55.68–70.88 52.30–73.80
QOLy
Mean7SD 9.374.78 10.375.05 0.118
Q1: the first quartile, Q3: the third quartile.
Respiratory complications: chronic obstructive pulmonary disease, emphysema, chronic respiratory failure, diffused
panbronchiolitis or bronchiectasis.
ySCG group, n ¼ 113; Controls, n ¼ 113.
z:%FEV1.0 ¼ FEV1.0/FCVratio.
ySCG group, n ¼ 111; Controls, n ¼ 112.
Y. Sano et al.424Distribution of responders was examined in each
subgroup. Stratified analysis on disease-type sub-
groups revealed significant improvement among
patients with atopic asthma, with a response rate
of 42.6% (n ¼ 29 vs. n ¼ 68) in the SCG group and
22.7% (n ¼ 15 vs. n ¼ 66) in Controls. Incidence of
responders was significantly higher in the SCG group
(P ¼ 0:017). However, among patients with non-
atopic asthma, response rate was 22.7% (n ¼ 10 vs.n ¼ 44) in the SCG group and 27.7% (n ¼ 13 vs.
n ¼ 47) in Controls, with no significant difference.
Stratified analysis on respiratory complications
and/or chronic sinusitis was performed. Patients
without complication showed significant improve-
ment, with a response rate of 37.5% (n ¼ 36 vs.
n ¼ 96) in the SCG group and 22.2% (n ¼ 22
vs. n ¼ 99) in Controls. On the other hand,
patients with complications showed no significant
ARTICLE IN PRESS
Table 3 Asthmatic medications during observation period.
SCG group Controls
(n ¼ 114) (n ¼ 114)
Inhaled corticosteroids
Beclomethasone dipropionate 27 23
Fluticasone propionate 73 82
Beclomethasone+fluticasone 2 4
Budesonide 12 5
Other asthmatic medications
No 0 0
Yes 114 114
Anti-LT drugs 56 62
Anti-allergy drugs 26 16
Slow-acting theophylline 105 97
Long-acting b2 agonists 85 76
Inhaled 13 12
Oral 47 44
Topical 34 31
Short-acting inhaled b2 agonists 82 86
Inhaled anti-cholinergics 22 13
Oral corticosteroidsy 49 48
Median daily dose: SCG group, 1600 ug/day (Q1–Q3: 1200–1600); Controls, 1600mg/day (Q1–Q3: 1200–1600).
yMedian daily dose: SCG group, 5mg/day (Q1–Q3: 5–5); Controls, 5mg/day (Q1–Q3: 5–8.17). Q1: the first quartile, Q3: the
third quartile.
Effects of nebulized sodium cromoglycate 425improvement, with a response rate of 18.2% (n ¼ 3
vs. n ¼ 16) in the SCG group and 42.9% (n ¼ 6 vs.
n ¼ 14) in Controls (Table 5).
Analysis of changes in FVC, FEV1.0, and %FEV1.0,
from observation period to the end of treatment,
showed no significant difference between groups
(Table 6). Changes in total ‘‘yes’’ responses on the
QOL questionnaire from pre-treatment to end of
treatment showed 1.773.93 in the SCG group and
1.473.38 in Controls. Scores were not signifi-
cantly different between groups (P ¼ 0:539).
No significant difference in analysis of changes in
asthmatic symptom scores were shown at any other
point of time (P ¼ 0:951). No significant difference
in treatment scores were noted between groups
(P ¼ 0:402).
Treatment was discontinued during the study for
the patients whose symptoms had exacerbated: 13
patients (discontinuation rate of 11.4%) in the SCG
group and 11 patients (discontinuation rate of 9.6%)
in Controls. No significant difference was identified
between groups (P ¼ 0:830).Safety
Adverse events occurred in 73 patients (58.9%) in
the SCG group and 67 patients (54.9%) in Controls.
Frequency of adverse events did not differ sig-nificantly between groups (P ¼ 0:607). Treatment
was discontinued as a result of adverse events in 9
patients (7.3%) in the SCG group and 7 patients
(5.7%) in Controls. Incidence regarding discontinua-
tion of treatment due to adverse events showed no
significant difference between groups (P ¼ 0:797).
Adverse reactions had occurred in 11 patients
(8.9%) in the SCG group and 10 patients (8.2%) in
Controls (Table 7), and no significant difference was
identified (P ¼ 1:000). Adverse reactions which
required discontinuation of the treatment had
occurred in 1 patient (0.8%) in the SCG group and
2 patients (1.6%) in Controls, and no significant
difference was seen (P ¼ 0:620).Discussion
Current asthma treatment guidelines in Europe, the
United States, and Japan have recommended
inhaled corticosteroids as the first choice for long-
term management of asthma. Dose of inhaled
corticosteroids and/or addition of other medica-
tions (e.g., long-acting inhaled b2 agonists, LTRAs,
oral slow-acting theophylline, antiallergic agents or
oral corticosteroids) as a second choice should be
considered according to the severity of asthma. If
asthma is insufficiently controlled by medium- to
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Y. Sano et al.428high-dose of inhaled corticosteroids, the combina-
tion with other asthmatic medications is recom-
mended, expecting additive and synergistic
effects.12–14 However, some patients15,16 treated
with high-dose of inhaled corticosteroids, inade-
quately controlled by additions of long-acting
inhaled b2 agonist or oral corticosteroids, received
no significant benefit from further additions of
LTRAs. This is attributed to significant airway
remodeling and intractable peripheral airway in-
flammation, as a consequence of reduced response
against treatment.
Severe refractory asthma is caused by repetition
of airway inflammation with involvement of mast
cells, eosinophils, T-cells, and other inflammatory
cells induced by various factors. These recurrent
inflammation causing structural changes (airway
remodeling) may lead to irreversible airway ob-
struction and airway hypersensitivity. Other com-
plications such as chronic bronchitis, chronic
emphysema, and chronic sinusitis may promote
refractoriness. Patients with such severe asthma
are occasionally taken to emergencies and hospi-
talized for intravenous therapy. These patients may
present insomnia due to aggravated cough, sputum,
and anxiety against nocturnal attacks, and treat-
ment with inhaled and oral corticosteroids is often
insufficient. In these cases, QOL is neglected not
only for patients, but also for their family mem-
bers. Nevertheless, adequate treatments against
severe refractory asthma is not established, and
further investigations supported by new clinical
evidences are warranted.
SCG is an anti-inflammatory agent that influences
a variety of mechanisms against corticosteroids.
SCG participates in various inhibitory effects among
the process, such as airway inflammation, release
of chemical mediators from mast cells,17 IgE
production,18 T-cell and eosinophil accumulation,19
eosinophil activation,20,21 allergic inflamma-
tion,22,23 inflammatory cytokine production,22 ac-
tivation of afferent sensory nerves (C-fibers),24 and
induction of cysteinyl leukotoriene synthesis.25
Combination therapy using SCG may be effective
in controlling severe refractory asthmatic symp-
toms. One report mentioned that adding of
nebulized SCG (alone or with b2 agonist inhaled
by nebulizer) in patients with severe asthma had
improved pulmonary functions and decreased re-
quirement of oral corticosteroids.8 Combination of
nebulized SCG can reduce the frequency of asthma
attacks, minimize the need for emergency care,
and hospitalization for intravenous therapy. Thus,
successful control can also be achieved in the
outpatient, which is one of the primary goals of
asthmatic treatment. Many cases were also experi-enced by the author, in which nebulized SCG had
improved asthmatic symptoms in patients with
severe asthma.
In this study, evaluation was done to see the
efficacy and safety when combining nebulized SCG
and inhaled corticosteroids in adults with poorly
controlled severe asthma despite treatment with
high-dose of inhaled corticosteroids and other
medications. Median dosage of inhaled corticoster-
oids in both SCG group and Controls was 1600 mg/
day (BDP-CFC equivalent dose). Although patients
were all taking other medications (oral corticoster-
oids, 42.5%; long-acting inhaled b2 agonists, 70.6%;
LTRAs, 51.8%; oral slow-acting theophylline,
91.2%), mean PEFmorning (median) during the ob-
servation period was 60.2% of predicted in the SCG
group and 54.5% of predicted in Controls. PEFmorning
was not significantly different between SCG group
and controls. However, when patients were strati-
fied into atopic and non-atopic groups, PEFmorning in
the atopic SCG group had significantly improved
compared to atopic controls. The change in
PEFmorning, between observation period and end of
treatment, were 13.50 L/min in SCG group and
2.25 L/min in controls
‘‘Responders’’ in each group were also evaluated
for further clinically significant parameter. In
PEFmorning, X20 L/min is considered to show dis-
tinct improvement in daily medical examinations.26
Response rate was 34.8% in the SCG group and
24.8% in Controls, with 10% of difference. Stratified
analysis showed a 20% of difference in
response rate in the subgroup of patients
with atopic asthma: 42.6% in the SCG group and
22.7% in Controls (P ¼ 0:017). This suggests that
addition of nebulized SCG is particularly effective
in patients with severe atopic asthma. Approxi-
mately 90–95% of asthmatic children are atopic. In
a randomized crossover study, b2 agonist+saline
(administered as a nebulized solution) and b2
agonist+SCG were compared, in children with
moderate-to-severe asthma.27 This reported sig-
nificant improvements in the b2 agonist+SCG group.
Given the differences between adult and childhood
asthma, our results in the atopic subgroup support
their results.
Evaluation of the effects on drugs in severe
asthmatic patients is difficult, and this study failed
to show significant differences between SCG and
saline. However, stratified analysis showed signifi-
cant improvement on SCG in the subgroup of atopic
asthma. To provide effective treatment for each
individual patient, consideration of which patients
are inclined to respond to nebulized SCG would be
necessary. Atopic asthma responds to inhaled
SCG, and is IgE dependent. Allergic airway inflam-
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Figure 1 Median changes (L/min) (the first quartile to the third quartile) in morning peak expiratory flow (PEFmorning)
during the observation period vs. the 8-week treatment period and the end of treatment in all patients. End of
treatment includes the last recorded value during treatment using trial drug, regardless of withdrawal or completion of
the study. Closed circle represents patients with inhaled sodium cromoglycate administration (SCG group), open square
represents patients with inhaled isotonic saline administration (Controls). NS: not significant (2-sample Wilcoxon test).
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Figure 2 Median changes (L/min) (the first quartile to the third quartile) in morning peak expiratory flow (PEFmorning)
during the observation period versus the 8-week treatment period and the end of treatment in patients with atopic
type. End of treatment includes the last recorded value during treatment using trial drug, regardless of withdrawal or
completion of the study. Closed circle represents patients with inhaled sodium cromoglycate administration (SCG
group), open square represents patients with inhaled isotonic saline administration (Controls). yPo0.05, significantly
different between 2 groups (2-sample Wilcoxon test). NS: not significant.
Effects of nebulized sodium cromoglycate 429mation proceeds following mechanism. Specific IgE
antibodies produced by B cells bind with mast
cells and eosinophils. Activation of these cells byallergens causes the release of mediators which
trigger asthmatic reactions. In addition, some
inflammatory mediators stimulate C-fiber term-
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Wilcoxon test), significantly different between 2 groups. NS: not significant.
Table 5 Incidence of responders in PEFmorning.
Group X20 L/min (responders) o20 L/min (non-responders) Total Fisher’s exact test
All patients
SCG n 39 (34.8) 73 (65.2) 112 0.110
Controls n 28 (24.8) 85 (75.2) 113
Atopic
SCG n 29 (42.6) 39 (57.4) 68 0.017
Controls n 15 (22.7) 51 (77.3) 66
Non-atopic
SCG n 10 (22.7) 34 (77.3) 44 0.636
Controls n 13 (27.7) 34 (72.3) 47
Without respiratory complications and/or chronic sinusitis
SCG n 36 (37.5) 60 (62.5) 96 0.028
Controls n 22 (22.2) 77 (77.8) 99 0.236
With respiratory complications and/or chronic sinusitis
SCG n 3 (18.8) 13 (81.2) 16
Controls n 6 (42.9) 8 (57.1) 14
Respiratory complications: chronic obstructive pulmonary disease, emphysema, chronic respiratory failure, diffused
panbronchiolitis or bronchiectasis.
Y. Sano et al.430inals, causing the release of neuropeptides such as
substance P. Meanwhile, allergens are processed by
antigen-presenting cells. When allergen is pre-sented to the cell surface, it is recognized and
activated by T cells, which leads to the production
of Th2 cytokines. IL-5 involves in eosinophil activa-
ARTICLE IN PRESS
Table 6 Changes in pulmonary function.
Evaluation time
Start of treatment
measured value
4 weeks change 8 weeks change End of treatment
change
FVCy
SCG group (n) 113 109 98 105
Median 2430 20 60 60
Q1–Q3 1900–3250 180–230 130–240 140–240
Controls (n) 113 106 97 109
Median 2430 10 0 0
Q1–Q3 1970–3020 180–150 190–140 220–150
Between-group
comparison
— P ¼ 0:670 P ¼ 0:072 P ¼ 0:106
FEV1.0
y
SCG group (n) 113 109 98 105
Median 1500 20 0 10
Q1–Q3 1130–2040 110–150 150–130 160–130
Controls (n) 113 109 97 109
Median 1540 35 0 10
Q1–Q3 1140–2060 140–100 120–120 140–110
Between-group
comparison
— P ¼ 0:135 P ¼ 0:947 P ¼ 0:877
%FEV1.0
y,z
SCG group (n) 113 109 98 105
Median 63.20 0.61 1.00 1.00
Q1–Q3 55.68–70.88 3.70–3.50 4.60–2.40 4.40–2.40
Controls (n) 113 106 97 109
Median 66.37 0.62 0.10 0.24
Q1–Q3 52.30–73.80 2.90–2.70 2.40–3.30 2.85–3.30
Between-group
comparison
— P ¼ 0:240 P ¼ 0:096 P ¼ 0:220
Q1: the first quartile, Q3: the third quartile.
Between-group comparison: 2-sample Wilcoxon test.
End of treatment includes the last recorded value during treatment using trial drug, regardless of withdrawal or completion
of the study.
ySCG group, n ¼ 113; Controls, n ¼ 113.
z%FEV1.0 ¼ FEV1.0/FCVratio.
Effects of nebulized sodium cromoglycate 431tion, IL-4 and IL-13 act on B cells to stimulate IgE
antibody production.28–31 SCG inhibits these various
reactions, as mentioned above. In atopic asthma,
clinically the number of Th2-type T cells is
increased in alveolar lavage fluid and blood. T-cell
activation occurs only with eosinophil infiltration.
SCG inhibits expression of VCAM-1 and ICAM-1
associated with eosinophil and T-cell infiltration.
This inhibitory effect may be antigen- and Th2-
specific,22,23 which accounts for more prominent
effect of SCG in atopic asthma. However, non-
atopic asthma lacks antigen specificity, and the role
of allergy-induced inflammation is relatively small.
Therefore, SCG may be less effective in non-atopic
asthma. Stratified analysis for factors other thandisease type, including respiratory complications
due to chronic obstructive pulmonary disease and/
or chronic sinusitis, may complicate evaluations on
the effects of SCG. In chronic obstructive pulmon-
ary disease, eosinophilic inflammation plays a
minor role, whereas neutrophilic inflammation
plays a major role, which makes nebulized SCG fail
to exert significant effects. Excluding these com-
plications, stratified analysis showed a response
rate of 37.5% in the SCG group and 22.2% in
Controls (P ¼ 0:028). The number of responders
was significantly higher on inhaled SCG with
nebulizer. Thus, SCG may be more effective on
severe refractory asthma without respiratory com-
plications or chronic sinusitis.
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Table 7 Adverse reactions reported during treat-
ment period.
Adverse reactions SCG
group
Controls
Itching 2 0
Skin eruption 0 1
Tremor 1 0
Headache 0 1
Numbness of lip 1 1
Fuzzy head 1 1
Dysgeusia 0 1
Somnolence 1 0
Queasy 3 0
Churning of stomach 2 0
Vomiting 1 0
Oral discomfort 0 2
Oesophagitis 1 0
Anorexia 1 0
Tongue rough 1 1
Borborygmus 0 1
ALP increased 0 1
Thirst 0 1
Dyspnoea 1 0
Cough 1 0
Haematocrit value
decreased
1 0
Fever 0 1
Malaise 0 1
Feels poorly 0 1
Weakness 1 1
Calf pain 1 0
Feeling hot 1 0
No. of reactions 21 15
No. of patients
reporting at least one
adverse event
11 10
Y. Sano et al.432Nebulized placebo solution (purified water with-
out active ingredients of nebulized SCG solution)
was initially considered for Controls, but worsening
of respiratory function was concerned when this
purified water was nebulized by asthmatic pa-
tients.32,33 Therefore saline was selected to mini-
mize the risks of inducing asthmatic attacks.
Isotonic saline reportedly had improved pulmonary
function in some cases. Even in this study, Controls
as a whole displayed improvements in PEFmorning
compared to observation period.
In conclusion, addition of nebulized SCG to the
treatment regime of adults with severe asthma is
considered to be effective. For the patients in the
subgroup of atopic asthma, nebulized SCG have
produced substantial improvements on PEFmorning
compared to nebulized saline. This finding is
consistent with the pharmacological profile of
SCG. Addition of nebulized SCG as second-linecontrol therapy should be considered in patients
with severe refractory atopic asthma who are
taking inhaled corticosteroids.Acknowledgments
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